SwastiChemEx: Bioeconomy - Initiative

Wednesday 2 April 2014

Bioeconomy - Initiative

 In 2012, the number of companies grew by only 2.3%, their workforce by 6.9 %, and their revenues  by 10.7%.

The ten top-selling drugs worldwide include five biopharmaceuticals. Medical biotech companies in Germany have so far not developed any blockbuster drug, and in 2012 they did not gain approval to market a new drug. However, a growing trend of the pharmaceutical industry is to outsource their research, which leads to increased cooperation between the pharmaceutical industry and biotech companies.
 
























Industrial biotech companies are benefiting from changes in politics and society. As part of the Bioeconomy Initiative, the Federal Government encourages unusual alliances between biotech companies and other industries. For example, microorganisms should in the future be used to convert CO2 emissions of the steel industry into basic chemicals and other high-value products.
 
Also, the use of renewable resources instead of fossil resources and the public awareness of bio-based products are growing. Due to this, chemical and consumer industry companies, such as BASF and DSM, cooperate more and more with biotech companies.

No comments:

Post a Comment